Image 1_Circulating growth differentiation factor-15 concentration and hypertension risk: a dose-response meta-analysis.tif by Zhengqing Yu (12641890)

“…Significant heterogeneity was detected in the pooled analysis and meta-regression analysis suggested that participants’ age and the prevalence of diabetes significantly accounted for the heterogeneity.…”

Image 2_Circulating growth differentiation factor-15 concentration and hypertension risk: a dose-response meta-analysis.tif by Zhengqing Yu (12641890)

“…Significant heterogeneity was detected in the pooled analysis and meta-regression analysis suggested that participants’ age and the prevalence of diabetes significantly accounted for the heterogeneity.…”

Table 4_Circulating growth differentiation factor-15 concentration and hypertension risk: a dose-response meta-analysis.docx by Zhengqing Yu (12641890)

“…Significant heterogeneity was detected in the pooled analysis and meta-regression analysis suggested that participants’ age and the prevalence of diabetes significantly accounted for the heterogeneity.…”

Table 1_Circulating growth differentiation factor-15 concentration and hypertension risk: a dose-response meta-analysis.docx by Zhengqing Yu (12641890)

“…Significant heterogeneity was detected in the pooled analysis and meta-regression analysis suggested that participants’ age and the prevalence of diabetes significantly accounted for the heterogeneity.…”

Table 3_Circulating growth differentiation factor-15 concentration and hypertension risk: a dose-response meta-analysis.docx by Zhengqing Yu (12641890)

“…Significant heterogeneity was detected in the pooled analysis and meta-regression analysis suggested that participants’ age and the prevalence of diabetes significantly accounted for the heterogeneity.…”

Table 2_Circulating growth differentiation factor-15 concentration and hypertension risk: a dose-response meta-analysis.docx by Zhengqing Yu (12641890)

“…Significant heterogeneity was detected in the pooled analysis and meta-regression analysis suggested that participants’ age and the prevalence of diabetes significantly accounted for the heterogeneity.…”

Table2_Causal relationship between plasma lipidome and four types of pancreatitis: a bidirectional Mendelian randomization study.xlsx by Runzhou Ma (19758996)

“…We obtained genetic variants associated with 179 lipid species from a Genome-wide association analysis of plasma lipidome. …”

Table4_Causal relationship between plasma lipidome and four types of pancreatitis: a bidirectional Mendelian randomization study.xlsx by Runzhou Ma (19758996)

“…We obtained genetic variants associated with 179 lipid species from a Genome-wide association analysis of plasma lipidome. …”

Table1_Causal relationship between plasma lipidome and four types of pancreatitis: a bidirectional Mendelian randomization study.xlsx by Runzhou Ma (19758996)

“…We obtained genetic variants associated with 179 lipid species from a Genome-wide association analysis of plasma lipidome. …”

Table5_Causal relationship between plasma lipidome and four types of pancreatitis: a bidirectional Mendelian randomization study.xlsx by Runzhou Ma (19758996)

“…We obtained genetic variants associated with 179 lipid species from a Genome-wide association analysis of plasma lipidome. …”

Table3_Causal relationship between plasma lipidome and four types of pancreatitis: a bidirectional Mendelian randomization study.xlsx by Runzhou Ma (19758996)

“…We obtained genetic variants associated with 179 lipid species from a Genome-wide association analysis of plasma lipidome. …”

Supplementary file 1_Characteristics, clinical evidence and implementation effects of conditional approvals for drugs in China, a pooled analysis from 2020 to 2023.docx by Li Yang (6520)

“…<p>In late 2019, the conditional approval process for drugs in China transitioned from a pilot project to a formal program. Our study comprehensively analyzed 103 conditional approvals (CAs) authorized by the National Medical Products Administration (NMPA) from 2020 to 2023, specifically focusing on their characteristics, clinical evidence, and implementation effects. …”

DataSheet1_Risk of bone fracture by using dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients wit... by Mohamed E. A. Mostafa (19834779)

“…The risk of fracture was identified with the follow-up duration for each class. We found a significant decrease in the fracture risk by about 87% associated with patients who used SGLT2 inhibitors in combination with other glucose-lowering medications, followed by SGLT2 inhibitors alone by about 67%, then GLP-1 receptor agonists by about 60%, and at last DPP-4 inhibitors by about 55%.…”

DataSheet2_Risk of bone fracture by using dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients wit... by Mohamed E. A. Mostafa (19834779)

“…The risk of fracture was identified with the follow-up duration for each class. We found a significant decrease in the fracture risk by about 87% associated with patients who used SGLT2 inhibitors in combination with other glucose-lowering medications, followed by SGLT2 inhibitors alone by about 67%, then GLP-1 receptor agonists by about 60%, and at last DPP-4 inhibitors by about 55%.…”

DataSheet3_Risk of bone fracture by using dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients wit... by Mohamed E. A. Mostafa (19834779)

“…The risk of fracture was identified with the follow-up duration for each class. We found a significant decrease in the fracture risk by about 87% associated with patients who used SGLT2 inhibitors in combination with other glucose-lowering medications, followed by SGLT2 inhibitors alone by about 67%, then GLP-1 receptor agonists by about 60%, and at last DPP-4 inhibitors by about 55%.…”

Table 1_Trends in cervical cancer incidence and mortality in the United States, 1975–2018: a population-based study.docx by Xianying Cheng (10677443)

“…</p>Conclusion<p>For cervical cancer cases diagnosed in the United States from 1975 to 2018, the overall incidence and mortality rates decreased significantly. However, there was an increase in the incidence and mortality of advanced-stage squamous cell carcinoma. …”

Trends and Disparities in Rates of Hypoglycemia Among Hospitalized Patients with Type II Diabetes by Paul A Heidenreich (13188712)

“…After adjustment for other patient characteristics, the youngest and oldest patients, and those hospitalized in earlier years (vs. 2022) had significantly higher rates of hypoglycemia. Black (adjusted odds ratio -aOR, 1.42 95% CI 1.36-1.49) or Hispanic patients (aOR 1.26 95% CI 1.17-1.35) had a greater risk of hypoglycemia compared with non-Hispanic White patients and women had borderline less hypoglycemia than men (aOR 0.95, 95% CI 0.89-1.00)</p><p dir="ltr">Conclusion: Inpatient hypoglycemia in the VA Health System has been declining though there are race, age and gender differences that remain unexplained. …”

Data Sheet 1_Impact of the SARS-COV-2 pandemic on access to health services in Angola: a focus on diagnosis and treatment services for tuberculosis.docx by Susanna Caminada (16789893)

“…</p>Results<p>There was a significant decline in access to TB services during the pandemic, with a substantial decrease in reported cases (−15.5% in 2020; −18.3% in 2021) and treatment rate (from 86% in 2019 to 68% in 2020), an increase in multidrug-resistant-TB (from 0.2% in 2018 to 2.1% in 2022) and TB/HIV co-infections (from 6% in 2018 to 8.8% in 2021). …”

Image4_Causal association between matrix metalloproteinases and diabetic neuropathy: a two-sample Mendelian randomization study.tif by Chao Bai (4428472)

“…Objective<p>Diabetic neuropathy (DN), a common and debilitating complication of diabetes, significantly impairs the quality of life of affected individuals. …”

Image2_Causal association between matrix metalloproteinases and diabetic neuropathy: a two-sample Mendelian randomization study.tif by Chao Bai (4428472)

“…Objective<p>Diabetic neuropathy (DN), a common and debilitating complication of diabetes, significantly impairs the quality of life of affected individuals. …”